|
Delayed
NSE India S.E.
10:59:07 08/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 2,479.10 INR | +1.11% |
|
+0.19% | +21.61% |
| 07/09 | Acucort wins trademark protection for Zeqmelit in Ukraine | FW |
| 20/08 | Glenmark Pharmaceuticals Limited Receives U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg (50 Mcg)/Spray | CI |
| Market Cap | 69TCr 731.63Cr 629.2Cr 591.78Cr 540.21Cr 1.01TCr 1.01TCr 7.02TCr 2.71TCr 35TCr 2.75TCr 2.69TCr 1,12900Cr | P/E 2027 * |
29.8x | P/E 2028 * | 24.8x |
|---|---|---|---|---|---|
| Enterprise Value | 66TCr 693.04Cr 596.02Cr 560.57Cr 511.72Cr 957.04Cr 960.14Cr 6.65TCr 2.57TCr 34TCr 2.6TCr 2.55TCr 1,06900Cr | EV / Sales 2027 * |
3.9x | EV / Sales 2028 * | 3.44x |
| Free-Float |
51.04% | Yield 2027 * |
0.16% | Yield 2028 * | 0.16% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| GLENMARK | Delayed | |
Bombay S.E.
| GLENMARK | Delayed |
Last Transcript : Glenmark Pharmaceuticals Limited
| 1 day | +0.94% | ||
| 1 week | +0.19% | ||
| Current month | -0.20% | ||
| 1 month | +9.94% | ||
| 3 months | +13.71% | ||
| 6 months | +16.88% | ||
| Current year | +21.61% |
| 1 week | 2,420 |  | 2,479.9 |
| 1 month | 2,222.5 | | 2,537.6 |
| Current year | 1,842 | | 2,537.6 |
| 1 year | 1,792.6 | | 2,537.6 |
| 3 years | 722.1 | | 2,537.6 |
| 5 years | 348.5 | | 2,537.6 |
| 10 years | 161.65 | | 2,537.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 01/01/2000 | |
Anurag Mantri
DFI | Director of Finance/CFO | 54 | 27/05/2025 |
Indrajit Bose
PSD | President | - | 15/09/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Cherylann Pinto
BRD | Director/Board Member | 58 | - |
| Chairman | 56 | 12/05/2011 | |
| Director/Board Member | 86 | 14/08/2009 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.11% | +0.19% | +20.62% | +218.59% | 731.63Cr | |
| -0.35% | -2.01% | +19.56% | +67.21% | 4.81TCr | |
| +0.43% | -4.92% | +38.96% | +117.62% | 3.99TCr | |
| -0.62% | -2.61% | -10.08% | +11.35% | 1.19TCr | |
| -0.84% | -1.99% | +13.37% | +82.22% | 1.22TCr | |
| -1.50% | -0.38% | +24.76% | +138.18% | 922.39Cr | |
| -0.86% | -3.20% | +23.76% | +38.38% | 741.15Cr | |
| +0.45% | -2.29% | +36.70% | -13.27% | 736.69Cr | |
| -0.32% | -1.85% | -46.31% | +22.01% | 517.14Cr | |
| +1.47% | +1.72% | +37.61% | +105.88% | 464.16Cr | |
| Average | -0.14% | -2.09% | +15.89% | +78.82% | 1.53TCr | |
| Weighted average by Cap. | -0.14% | -3.09% | +21.53% | +83.08% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 17TCr 177.56Cr 152.7Cr 143.62Cr 131.1Cr 245.2Cr 245.99Cr 1.7TCr 658.23Cr 8.6TCr 666.81Cr 652.23Cr 27TCr | 19TCr 197.86Cr 170.16Cr 160.04Cr 146.09Cr 273.23Cr 274.11Cr 1.9TCr 733.48Cr 9.58TCr 743.04Cr 726.79Cr 31TCr |
| Net income | 2.31TCr 24Cr 21Cr 20Cr 18Cr 34Cr 34Cr 234.36Cr 91Cr 1.18TCr 92Cr 90Cr 3.77TCr | 2.77TCr 29Cr 25Cr 24Cr 22Cr 40Cr 41Cr 280.97Cr 108.61Cr 1.42TCr 110.02Cr 107.61Cr 4.52TCr |
| Net Debt | -3.65TCr -39Cr -33Cr -31Cr -28Cr -53Cr -53Cr -370.04Cr -143.04Cr -1.87TCr -144.9Cr -141.73Cr -5.95TCr | -4.8TCr -51Cr -44Cr -41Cr -37Cr -70Cr -70Cr -486.79Cr -188.16Cr -2.46TCr -190.61Cr -186.45Cr -7.83TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/26/08 | ₹2,479.10 | +1.11% | 1,29,197 |
| 07/26/07 | ₹2,451.90 | +0.60% | 2,67,568 |
| 04/26/04 | ₹2,437.20 | -0.89% | 4,12,728 |
| 03/26/03 | ₹2,459.00 | -0.04% | 4,81,343 |
| 02/26/02 | ₹2,460.00 | -0.42% | 5,16,029 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GLENMARK Stock
Select your edition
All financial news and data tailored to specific country editions
